Rob Williams-Lambkin

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.

Journal: The Journal of infectious diseases
Published: November 12, 2020

A COVID-19 human viral challenge model. Learning from experience.

A COVID-19 human viral challenge model. Learning from experience.

Journal: Influenza and other respiratory viruses
Published: July 07, 2020

Inhibition of viral and bacterial trigger-stimulated prostaglandin E2 by a throat lozenge containing flurbiprofen: An in vitro study using a human respiratory epithelial cell line.

Inhibition of viral and bacterial trigger-stimulated prostaglandin E2 by a throat lozenge containing flurbiprofen: An in vitro study using a human respiratory epithelial cell line.

Journal: SAGE open medicine
Published: February 17, 2020

Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".

Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".

Journal: Antimicrobial agents and chemotherapy
Published: December 23, 2017

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process.

The manufacturing of human viral challenge agents for use in clinical studies to accelerate the drug development process.

Journal: BMC research notes
Published: December 08, 2017

The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.

The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.

Journal: Respiratory research
Published: September 18, 2017

Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

Journal: Antimicrobial agents and chemotherapy
Published: June 06, 2017

The effective rate of influenza reassortment is limited during human infection.

The effective rate of influenza reassortment is limited during human infection.

Journal: PLoS pathogens
Published: October 14, 2016

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.

Correction: Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.

Journal: PloS one
Published: June 10, 2016

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

Journal: The New England journal of medicine
Published: November 19, 2015

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.

An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.

Journal: PloS one
Published: October 22, 2015

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.

Journal: PloS one
Published: August 24, 2015
Showing 1-12 of 21

Last Updated: 09/26/2026